These data indicated that SCE selectively decreased Smad3 expression and then inhibited TGF-β/Smad3 signaling activation, which ameliorated fibrotic responses in CFs. This evidence concerns the gene SMAD3 and myalgic encephalomeyelitis/chronic fatigue syndrome.